Syntegon, a strategic partner of the pharmaceutical and food industries, is continuing its successful development and preparing for the next phase of its growth strategy. With the sale of its former site in Waiblingen to Andreas Stihl AG & Co. KG, and the planned relocation of its production and administration activities to Fellbach and Bad Cannstatt (Stuttgart) this year, Syntegon is setting the ideal conditions for further growth.
State-of-the-art pharma site in Fellbach
The activities of the Pharma Solid business unit located in Waiblingen will move to a dedicated pharma site in neighboring Fellbach in the second half of 2025. A modern production center is being established there, significantly increasing manufacturing capacities and enabling further growth. The site will feature an optimized production and office concept tailored to the needs of the growing pharma industry.
Business Excellence Center in Bad Cannstatt
Syntegon will establish its central administrative functions in a Business Excellence Center in the Stuttgart district of Bad Cannstatt in the third quarter of 2025. From there, they will optimally support the worldwide expansion of the Syntegon Group under modern working conditions. The sustainably developed office building is conveniently located close to Stuttgart’s main railway station and airport.
Waiblingen property in good hands
Syntegon has sold its previous location in Waiblingen to Andreas Stihl AG & Co. KG. Both parties signed the corresponding purchase agreement on March 31. “We are pleased that our long-standing property will be in good hands,” says Torsten Türling, chief executive officer of the Syntegon Group.
Future-oriented strategy
The spatial changes are an important step in Syntegon‘s growth strategy. “With the new locations in Fellbach and Bad Cannstatt, we are creating the ideal conditions for further growth and will even better fulfill our role as a strategic technology partner to the global pharmaceutical industry,” says Torsten Türling.
